The Latest Breaking News from Novo Nordisk

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

The medication is currently available in 16 other countries

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

Novo Nordisk faces a challenge turning around the fortunes of residents in a major Danish manufacturing hub.

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…